Presentations highlight advances in MRD, precision oncology, and real-world evidence across solid tumors and hematologic malignancies
On May 26, 2026, NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced it will showcase eight scientific abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29–June 2, 2026, in Chicago (booth #32130). The abstracts demonstrate NeoGenomics’ expanding capabilities across the company’s clinical oncology testing and data solutions, spanning hematologic malignancies, solid-tumor genomic profiling, the real-world impact of insurance coverage gaps on next-generation sequencing (NGS) testing, and the detection of circulating tumor DNA (ctDNA) through molecular residual disease (MRD). These findings include an online presentation on the utilization of RaDaR® ST in a colorectal cancer cohort, as reflected in an interim analysis from a collaboration with investigators at MD Anderson Cancer Center.
To support biopharma partners advancing ADCs, BiTES, bispecifics, radioligands, and targeted therapies, NeoGenomics will highlight new biomarkers, including B7-H3, CD137, EZH2, and PRMT5. The company is also developing a low-sample-input acute myeloid leukemia (AML) MRD flow assay designed to deliver higher sensitivity and faster turnaround times compared to currently available assays. This approach may enable more confident relapse risk prediction, therapeutic response assessment, and MRD endpoint tracking in hematologic trials, even when sample availability is limited.
NeoGenomics will also debut its updated mission, partnering with physicians to deliver actionable insights that guide personalized treatment decisions and improve outcomes, and a new vision of a world where every cancer treatment decision is as personal as the patient. Both will be reflected throughout the booth, alongside the company’s new tagline, “Answers Are in Our DNA.”
“A cancer diagnosis is the beginning of a long road, and NeoGenomics is committed to being there from first diagnosis through recurrence monitoring,” said Tony Zook, CEO of NeoGenomics. “The breadth of our ASCO research and a sharpened mission reflect our commitment to providing personalized answers for every cancer patient.”
Presentations and online abstracts at ASCO include:
- Poster #177: Bridging the Gap Between Clinical Utility and Coverage: Real-World Impact of Unreimbursed NGS Testing
- Session: Quality Care/Health Services Research
- Monday, June 1, 9 AM to 12 PM CDT | Hall A
- Poster #337: From Infancy to Young Adulthood: Exploring the Divergent Genomic Mechanisms That Drive AML
- Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
- Monday, June 1, 9 AM to 12 PM CDT | Hall A
- Poster #129a: Interception of Molecular Relapse in Breast Cancer: The SURVIVE HERoes Study (NCT06643585)
- Session: Breast Cancer—Local/Regional/Adjuvant
- Monday, June 1, 1:30 to 4:30 PM CDT | Hall A
- Poster #135a: The SURVIVE Study: Re-evaluating Follow-up in Early Breast Cancer
- Session: Breast Cancer—Local/Regional/Adjuvant
- Monday, June 1, 1:30 to 4:30 PM CDT | Hall A
- Online Abstract: Concordance of liquid biopsy and tissue CGP for identification of guideline-recommended actionable variants
- Online Abstract: Real-world evidence for comprehensive genomic profiling in myeloid malignancies: changes in detection and clinical impact
- Online Abstract: Exploration of tumor-informed ctDNA detection and dynamics in a real-world cohort of colorectal cancer patients from the MD Anderson Cancer Center
- Online Abstract: Clinical actionability and molecular landscapes of fusion-driven sarcomas: A multi-modal integration analysis of comprehensive genomic profiling, targeted RNA-sequencing, and PD-L1 expression
About NeoGenomics
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to deliver timely, actionable insights that guide personalized care decisions. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, England.